Amylyx Avexitide Pivotal Data Due This Quarter
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Amylyx Pharmaceuticals is set to read out pivotal study results for its drug avexitide later this quarter, with the source noting the outcome could support the drug's regulatory approval.
- Avexitide is being developed to halt severe, uncontrolled drops in blood sugar that some patients experience after undergoing stomach-reducing surgery for weight loss.
- The readout comes exactly two years after Amylyx voluntarily pulled its ALS drug off the market following a follow-on study that showed it wasn't helping patients — a move the source describes as both "rocked" and "lauded."
- The targeted indication is a rare endocrine disorder, positioning avexitide for a niche subset of post-bariatric surgery patients who experience dangerous hypoglycemia.
Why it matters: A positive readout would let Amylyx rebuild credibility two years after its ALS withdrawal and potentially secure approval for a drug with no other clear competitors in the post-bariatric hypoglycemia space. For the small population of post-surgery patients who experience severe blood sugar crashes, approval would mean a first targeted treatment option.
